What we do Granules India Ltd is a vertically integrated pharmaceutical company manufacturing active pharmaceutical ingredients, formulation intermediates, and finished dosages with global market presence. |
Founded in 1,991 |
Market share Leader in off-patent drugs like Paracetamol, Ibuprofen, and Metformin; strong US and European market presence. |
Problem solved Addresses supply security and cost competitiveness in essential generic drugs, ensuring reliable availability of APIs and formulations. |
Top clients or who we serve Supplies global pharma branded and generic companies; operates B2B with growing B2C OTC offerings in the US. |
Key management Dr. Krishna Prasad Chigurupati (Chairman & Managing Director) with advanced pharmaceutical expertise leads the company. |
Our journey and innovations Established in 1991, grew via vertical integration, acquisitions, and expanded R&D with recent focus on peptides and green technologies. |
Where we operate India-focused manufacturing and R&D; subsidiaries in US, Europe, and Switzerland; exports worldwide including US, Europe, Brazil, Canada. |
Top products or what we offer API, Pharmaceutical Formulation Intermediates, Finished Dosages; specialty APIs, peptides, oncology products, and CDMO services. |
Top brands Flagship products include Paracetamol, Ibuprofen, Metformin; leading US portfolio with multiple ANDA approvals; Ascelis Peptides brand launched. |
Raw materials needed Bulk chemical intermediates and raw materials for pharmaceutical synthesis, including raw compounds for APIs and peptides. |
Raw materials supplier Supplied by global chemical manufacturers and local suppliers adhering to pharmaceutical standards. |
Recurring vs cyclical contribution Majority of revenue is recurring from long-term supply contracts for APIs, PFIs, and finished dosage formulations. |
Our industry position Among top global suppliers in off-patent APIs and formulations with strong compliance and expanding specialty portfolio. |
Financial highlights FY 2024-25 revenue of ₹4481.61 Cr consolidated; PAT ₹501.52 Cr; EBITDA margin steady at 22.2%; growing R&D investment. |
Geographical revenue split Approximately 94% revenue from international markets (US, Europe), balance from India. |
Order book Order pipeline supported by multiple ANDA filings and USFDA approvals supporting future growth. |
Whats driving growth Growth driven by expanding finished dosage segment, R&D innovations, ANDA approvals, and strategic acquisitions like Senn Chemicals. |
Our future plans Scaling peptide production, continuous process APIs, green energy initiatives, and expanding formulations capacity globally. |
Our green promise Commitment to net-zero emissions by 2050, renewable energy use, waste recycling, and sustainable manufacturing practices. |
Our people and values Over 400 scientists, fostering innovation, inclusion, and ethical business aligned with global standards. |
Key challenges ahead Regulatory compliance risks, API raw material price volatility, and global supply chain uncertainties. |
Interesting facts First in India to set up large multi-unit pellet system manufacturing; pioneering continuous manufacturing for APIs. |
Risks and strategy Mitigates regulatory risks by robust compliance; addresses raw material risks via backward integration; growth through innovation and diversification. |
